6001

Shanghai Fosun Pharmaceutical Group Co Ltd

600196.SHG fosunpharma.com + Research + Basket
ISIN CNE000000X38
Employees 40,603
Phone 86 21 3398 7000
Fiscal year end December
IPO Jun 25, 1998
Address Building A, Shanghai, China, 200233
23.58
-0.08 (-0.34%)
CNY · SHG
52-week range
20.85
29.13
Trading at 33% of the 52-week range
Market Cap
62.97B
P/E Ratio
17.73
Forward P/E
17.76
Book Value
18.93
Div. Yield
1.65%
% Institutions
7.83%
% Insiders
43.03%

1 Year

-17.2%

3 Year

-17.9%

10 Year

+4.6%
Description

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

Actions

Add an action for 600196.SHG, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Ms. Xiaohui Guan Executive Co-Chairman 1971
Mr. Yuqing Chen Executive Chairman 1975
Dr. Yi Liu CEO, Chair of Fosun MedTech, Co-Chair of Innovative Medicines Division & Exec Director 1975
Mr. Deyong Wen Executive Vice Chairman 1971
Ms. Rongli Feng Executive President & Chief Human Resources Officer 1975
Ms. Jing Li Co-President and CEO of Mature Products and Manufacturing Business Unit 1972
Dr. Xingli Wang M.D., Ph.D. Co-President & CEO of the Innovative Drugs Business Unit 1962
Mr. Xiang Li DPHIL SVP, Co-President & CSO of the Innovative Drugs Business Unit 1966
Ms. Jia Yan Chief Accountant, Co-CFO & Assistant to the President and Employee Director 1982
Ms. Yue Zhu VP & GM of Legal Department 1977

Financial Highlights

▼
Market Cap: $62.97B
EBITDA: $6.45B
P/E Ratio: $17.73
Book Value: $18.93
Dividend/Share: $0.39
Dividend Yield: 1.65%
Earnings/Share: $1.33
Profit Margin: 8.23%
Operating Margin: 9.51%
ROA (TTM): 1.52%
ROE (TTM): 7.00%
Revenue (TTM): $42.73B
Revenue/Share (TTM): $16.22
Earnings Growth (YOY): 16.20%
Revenue Growth (YOY): 1.40%

Valuation Metrics

Enterprise Value: $83.46B
Trailing P/E: 17.73
Forward P/E: 17.76

Shares Statistics

Shares Outstanding: 2.12B
Shares Float: 1.65B
% Insiders: 43.03%
% Institutions: 7.83%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$41.50B
Cost of Goods Sold
adjust
$-22.39B
Gross Profit
subtotal
$19.12B
SG&A
adjust
$-6.80B
R&D
adjust
$-3.56B
Other Operating Expense
adjust
$-6.23B
Operating Income
subtotal
$2.52B
Other / Non-Operating Items
adjust
$846.25M
Net Income
subtotal
$3.37B

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about 600196.SHG!